Cartesian Therapeutics Inc
RNAC
Get informed when a big investor buys or sells
+ FollowMarket Cap$216.25M
Close$
$3.75
49% downside
Current Fair Value
49% downsideOvervalued by 49% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $216.25 Million |
|---|---|
| Enterprise Value | $86.45 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.02 |
| Beta | 0.62 |
| Outstanding Shares | 29,467,130 |
Return
| Return on Equity | 122.93% |
|---|---|
| Return on Assets | -48.31% |
| Return on Invested Capital | -10.67% |
Valuation & Multiples
| P/E Ratio | -1.24 |
|---|---|
| PEG | 9.1 |
| Price to Sales | - |
| Price to Book Ratio | -1.47 |
| Enterprise Value to Revenue | 58.53 |
| Enterprise Value to EBIT | -2.72 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | -0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.88
Average shareholder expectationRevenue Estimate
$179,667
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.02
Average shareholder expectationRevenue Estimate
$160,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2177▲ 21.77% |
|---|---|
| Total Calls | 143,300▲ Infinity% |
| Total Puts | 31,200▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 29.61%▲ 2.98% |
|---|---|
| Total Invested | $90.79M▲ 106.67% |
| Investors Holding | 101▲ 19.00% |
ESG Score
No data
About Cartesian Therapeutics Inc
81 employees
CEO: Carsten Brunn selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vac...